Literature DB >> 2844445

Lung carcinoid with Cushing's syndrome: control of serum ACTH and cortisol levels using SMS 201-995 (sandostatin).

P R Hearn1, C L Reynolds, K Johansen, N J Woodhouse.   

Abstract

Two patients with Cushing's syndrome due to lung carcinoid tumours were given the long-acting somatostatin analogue SMS 201-995 (Sandostatin). One received a single 50 micrograms dose which produced a 50% reduction in circulating ACTH levels within 4 h. The other has been maintained in clinical and biochemical remission for 10 weeks on 100 micrograms tid. This is the first report of the successful use of SMS 201-995 in carcinoid-induced Cushing's syndrome, and suggests that this hormone analogue could be valuable in the long term medical management of such patients.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2844445     DOI： 10.1111/j.1365-2265.1988.tb03654.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN： 0300-0664            Impact factor:   3.478


  13 in total

1.  Diagnosis and treatment of Cushing's syndrome. Cushing's syndrome: current clinical problems, symposium. Padova, October 19-20, 1990.

Authors: 
Journal:  J Endocrinol Invest       Date:  1992-03       Impact factor: 4.256

2.  Cushing's Disease: Sustained remission in five cases induced by medical therapy with the dopamine agonist cabergoline.

Authors:  Omayma Elshafie; Anjum Osman; Fatima Aamer; Ali Al-Mamari; Njy Woodhouse
Journal:  Sultan Qaboos Univ Med J       Date:  2012-11-20

3.  Adrenocorticotropic Hormone-Dependent Cushing's Syndrome: Use of an octreotide trial to distinguish between pituitary or ectopic sources.

Authors:  Omayma T El-Shafie; Nooralddin Al-Saffi; Ahmed Al-Sajwani; Nicholas Woodhouse
Journal:  Sultan Qaboos Univ Med J       Date:  2015-01-21

4.  Palliative therapy of an ectopic Cushing's syndrome due to a metastatic carcinoid tumor.

Authors:  E Kornely; R Schlaghecke; F A Horster
Journal:  Klin Wochenschr       Date:  1991-02-26

Review 5.  Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.

Authors:  Marialuisa Appetecchia; Roberto Baldelli
Journal:  J Exp Clin Cancer Res       Date:  2010-03-02

6.  ACTH-secreting bronchial carcinoid: a diagnostic and therapeutic challenge.

Authors:  J H McDermott; H Thabit; N Hickey; C Thompson; E Gaffney; V Young; S Sreenan
Journal:  Ir J Med Sci       Date:  2008-05-31       Impact factor: 1.568

7.  Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion.

Authors:  B Ambrosi; D Bochicchio; C Fadin; P Colombo; G Faglia
Journal:  J Endocrinol Invest       Date:  1990-03       Impact factor: 4.256

Review 8.  Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.

Authors:  P E Battershill; S P Clissold
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

9.  Uneventful octreotide LAR therapy throughout three pregnancies, with favorable delivery and anthropometric measures for each newborn: a case report.

Authors:  Deeb Daoud Naccache; Adnan Zaina; Zila Shen-Or; Michal Armoni; George Kontogeorgos; Ali Yahia
Journal:  J Med Case Rep       Date:  2011-08-16

Review 10.  Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives.

Authors:  Roberto Baldelli; A Barnabei; L Rizza; A M Isidori; F Rota; P Di Giacinto; A Paoloni; F Torino; S M Corsello; A Lenzi; M Appetecchia
Journal:  Front Endocrinol (Lausanne)       Date:  2014-02-07       Impact factor: 5.555
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.